Unione Europea - italiano - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - agenti antineoplastici - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. per ulteriori informazioni sullo stato del recettore del fattore di crescita epidermico umano 2 (her2), fare riferimento alla sezione 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. per ulteriori informazioni sullo stato her2, fare riferimento alla sezione 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - erlotinibum - compresse rivestite con film - erlotinibum 25 mg ut erlotinibi hydrochloridum, lactosum monohydricum 23.98 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidi methacrylici copolymerum a, natrii hydrogenocarbonas, e 171, pro compresso obducto corresp. natrium 0.2 mg. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - erlotinibum - compresse rivestite con film - erlotinibum 100 mg ut erlotinibi hydrochloridum, lactosum monohydricum 95.93 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidi methacrylici copolymerum a, natrii hydrogenocarbonas, e 171, pro compresso obducto corresp. natrium 0.7 mg. - onkologikum - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - erlotinibum - compresse rivestite con film - erlotinibum 150 mg ut erlotinibi hydrochloridum, lactosum monohydricum 143.9 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, acidi methacrylici copolymerum a, natrii hydrogenocarbonas, e 171, pro compresso obducto corresp. natrium 1.1 mg. - onkologikum - synthetika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

mylan s.p.a. - erlotinib - erlotinib

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sun pharmaceutical industries (europe) b.v. - erlotinib - erlotinib

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - erlotinib - erlotinib

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - erlotinibum - compresse rivestite con film - erlotinibum 25 mg ut erlotinibi hydrochloridum, lactosum monohydricum 23.98 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii hydrogenocarbonas, pro compresso obducto corresp. natrium 0.177 mg. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - erlotinibum - compresse rivestite con film - erlotinibum 100 mg ut erlotinibi hydrochloridum, lactosum monohydricum 95.93 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii hydrogenocarbonas, pro compresso obducto corresp. natrium 0.71 mg. - farmaco - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - erlotinibum - compresse rivestite con film - erlotinibum 150 mg ut erlotinibi hydrochloridum, lactosum monohydricum 143.90 mg, cellulosum microcristallinum, carboxymethylamylum natricum a, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, natrii hydrogenocarbonas, pro compresso obducto corresp. natrium 1.064 mg. - farmaco - synthetika